i mean he still at advaxis or not?

Is Chris Duke still working?

If no deals done by September with money upfront, I'm afraid KEN will do another offering,we will drop below $1.00 for sure if that came true. It will be nightmare for longs! New offering really no damage to the company, at least can survive another year. That's what I'm afraid of. New deals making not that easy. Look Dan and Lombardo, nothing from them. Lombardo even got connections with capital raising, he didn't get deals done either. Two more month left. Lets see Ken can achive something

I just couldn't believe some Chinese bio companies are trading at $20, $30, even $100 PPS, what's wrong with all these American small cap bio stocks. Advaxis is one of them!

I think Merck is taking PSA HOT, BMY is taking NSCLC HOT or AMGEN

That was fast work from FDA! good work KEN! Seems to me deals are imminent at any moment!

Another possibility Sean Harper is going to CytomX

Seems Advaxis already have in mind who will be the partner for NSCLC and Prostate.
Future ADXS-HOT constructs will be selected from the
following five tumor types: Breast, colorectal, bladder,
ovarian, head and neck cancers

In discussions with multiple parties( who?)

Which BP is the leader in these tumor types?Breast, colorectal, bladder,
ovarian, head and neck cancers

If Amgen gets HOT deal, you know what will happen, we may see new high pps!I would say we all set for buyout!

Read HOT abstract again

https://www.advaxis.com/wp-content/uploads/2018/04/HOT-AACR-Abstract-Final-2018.pdf

He will stay at Amgen until September, I'm wondering HOT deal is about to close that time also!

Great article! NEO is the future!
https://www.statnews.com/2017/07/05/cancer-vaccine-melanoma/

Maybe he is going to XENCOR

So Harper is bullish on NEO insteadof CAR-T? Thats what means?
Analysts at Jefferies said in a note to clients: “More exec changes in the industry. Neutral impact to Amgen for Street perspective.” The firm says that Harper “was fairly well-regarded in the biotech community given advancement of numerous drugs (PCSK9, CGRP, Bone health) and recently well known for his bullishness on bi-specifics instead of CAR-T.”

Nice article about Sean Harper!

https://endpts.com/amgen-rd-chief-sean-harper-hits-the-exits-with-a-one-way-ticket-to-early-stage-biotech/

Dr. Harper joined Amgen in 2002 as vice president, Development, and has held several leadership roles, including heading the establishment of Amgen's Medical Sciences capability, a translational medicine group focused on biomarker discovery, development, and integration into early phase clinical studies. Dr. Harper served as vice president of Global Regulatory Affairs and Safety before assuming the role of senior vice president of Global Development and Corporate Chief Medical Officer. He became executive vice president, Research and Development in February 2012.

Prior to joining Amgen, Dr. Harper was senior director of clinical genomics at Merck Research Laboratories. He attended medical school at the University of California at San Francisco, completed internal medicine and gastroenterology training at the Massachusetts General Hospital, and was a postdoctoral fellow in the laboratory of Phillip A. Sharp at the Massachusetts Institute of Technology.

Sean made 6 million last year with stock options, I guess he is opening his own Bio company!

He is only 55 years old, he wants to make more money or he made enough money? Do we need a research and development president at Advaxis?

If that come true, you know what will happen to advaxis! I just don't think so, Advaxis couldn't afford to hire this kind of people!

Sean Harper, Amgen’s head of research and development, is leaving the company to pursue opportunities in the early-stage biotechnology space.

I think he was the guy responsible for NEO!

"Amgen's collaboration with Advaxis leverages and enhances our development and commercialization expertise in novel immuno-oncology treatments," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "We look forward to partnering with Advaxis to advance this highly targeted and patient-specific treatment option for patients."

Enrolled patients will undergo a biopsy, and Advaxis will then manufacture an investigational personalized treatment for each patient based on an analysis of their tumor neoantigen mutations, which will be ready to dose within 8 weeks of the initial biopsy.

Second dosing is about middle of August, maybe after second dosing!

Time to get in to make some trades for short term gain!

Maple, Dan made some mistakes, but I think DAN wants the stock to go up to $50 as Well, because he is holding a lot shares and he wants to be rich too! At this moment, everybody wants the stock go up, except the shorts which is at very lowest level. JMHO

I just don't see any deal announcement before September CC. If no partner will be found for AXAL, KEN will kill AXAL trial! that is what he said last CC. I personally really dont' care AXAL anymore, i hope Ken can sign some good deals with HOT! focus on NEO, no worry about funding for NEO. If he can get HOT with Amgen and Merck, then we are all set for the buyout later!

The whole sector is cooling down at this moment, summer time is not a good time to announce deal time. Ken is waiting for the right moment to strike. I can tell you 2019 looking very good for Advaxis!

According to slide 20, NEO pre-data available in 2019, we may see it early 2019. imagine HOT deals coming soon, PSA data Q1 2019, then Neo data. That's good plan!

Two new positions posted, director, human resource, Sr. scientist, do they have enough money to pay for them? LOL

Just checked yahoo board, lot of shorts over there, Miket is out, LOL

Every time we expecting good news from Advaxis, they surprised us with bad news! Let's wait this time to see what news Ken will surprise us!

As Health-Care IPO Boom Continues, Wall Street Tells Investors to Buy

https://www.bloomberg.com/news/articles/2018-07-23/as-health-care-ipo-boom-continues-street-tells-investors-to-buy


Health-care companies are going public at a startling rate and analysts are as bullish as ever as they kick off initiations of five companies today.

The companies range from one developing so-called “off the shelf” immunotherapies to a commercial-stage medical device maker with a non-invasive treatment for depression. Even as two of the five companies have slid from their initial valuations, only one company has so far earned anything less than a buy from the analysts who underwrote the deals.

sorry my friend, HOT is very hot!Amgen might takes all!

So you will sell at $5.00?

I'm sure PPS will continue to rise before the deal, remember someone will know the news before us!

No rush for news, wait after September!

Brad Loncar on Twiter: Today was $IBB's lowest volume day of the year. Everybody's out for summer.

An ancient volcano is about to erupt soon!

Yes, Amgen paid $1 Billion for BioVex back in 2011

published in July AACR Journals 2018, KEN! get AMGEN to pay the right price!

Neoantigens that fail to elicit measurable T cell responses following peptide immunization can control tumor growth when delivered using a Listeria-based immunotherapy platform

http://cancerres.aacrjournals.org/content/78/13_Supplement/LB-150

Replimune Readies $100 Million U.S. IPO, same technology as Advaxis.

The firm pioneered the first FDA-approved oncolytic immunotherapy - a neoantigen vaccine specific for patients' tumors. This is a new class of cancer treatment which uses the ability of certain viruses to selectively replicate and kill tumors.

https://seekingalpha.com/article/4186434-replimune-readies-100-million-u-s-ipo

wait and see. no coincidence with 7 million shares.